Bacitracin-Neomycin + Bacitracin-Neomycin-Polymyxin With Hydrocortisone Acetate 1 % + Polymyxin With Hydrocortisone Acetate 1 %
18 adverse event reports submitted to the FDA
Active Ingredients
Administration Routes
Species Affected
Most Affected Breeds
Most Reported Reactions
Outcome Breakdown
Data Summary
| Metric | Value |
|---|---|
| Total adverse event reports | 18 |
| Reports involving death | 0 |
| Case-fatality rate (reported events) | 0.0% |
| Distinct species in reports | 5 |
| Distinct breeds in reports | 13 |
| Distinct reactions reported | 20 |
| Active ingredients on file | 3 |
Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.
Bacitracin-Neomycin + Bacitracin-Neomycin-Polymyxin With Hydrocortisone Acetate 1 % + Polymyxin With Hydrocortisone Acetate 1 % Adverse Event Insights
The FDA Center for Veterinary Medicine database currently holds 18 adverse event reports referencing Bacitracin-Neomycin + Bacitracin-Neomycin-Polymyxin With Hydrocortisone Acetate 1 % + Polymyxin With Hydrocortisone Acetate 1 %, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Bacitracin-Neomycin, Bacitracin-Neomycin-Polymyxin With Hydrocortisone Acetate 1 %, Polymyxin With Hydrocortisone Acetate 1 %. Reported administration routes include Ophthalmic, Unknown, Topical, Intraocular. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.
The species most frequently named in Bacitracin-Neomycin + Bacitracin-Neomycin-Polymyxin With Hydrocortisone Acetate 1 % + Polymyxin With Hydrocortisone Acetate 1 % reports are Dog (9 reports), Unknown (4 reports), Cat (3 reports), with Dog accounting for the largest share. Within those species, Unknown (5), Retriever - Labrador (2), Domestic Shorthair (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.
The most commonly reported clinical signs associated with Bacitracin-Neomycin + Bacitracin-Neomycin-Polymyxin With Hydrocortisone Acetate 1 % + Polymyxin With Hydrocortisone Acetate 1 % are Eye redness (3), Diarrhoea (3), Swollen eye (2), Vomiting (2). Of the 14 reports with a coded outcome, Outcome Unknown is the leading category at 57.1%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Bacitracin-Neomycin + Bacitracin-Neomycin-Polymyxin With Hydrocortisone Acetate 1 % + Polymyxin With Hydrocortisone Acetate 1 %.
Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates
Read our methodology — how this data is sourced, computed, and verified.